Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin

Lawton J Stubbert1,3, Jennifer M Smith1,3 and Bruce C McKay*1,2,3

Abstract

Background: One of the most commonly used classes of anti-cancer drugs presently in clinical practice is the platinum-based drugs, including cisplatin. The efficacy of cisplatin therapy is often limited by the emergence of resistant tumours following treatment. Cisplatin resistance is multi-factorial but can be associated with increased DNA repair capacity, mutations in p53 or loss of DNA mismatch repair capacity.

Methods: RNA interference (RNAi) was used to reduce the transcription-coupled nucleotide excision repair (TC-NER) capacity of several prostate and colorectal carcinoma cell lines with specific defects in p53 and/or DNA mismatch repair. The effect of small inhibitory RNAs designed to target the CSB (Cockayne syndrome group B) transcript on TC-NER and the sensitivity of cells to cisplatin-induced apoptosis was determined.

Results: These prostate and colon cancer cell lines were initially TC-NER proficient and RNAi against CSB significantly reduced their DNA repair capacity. Decreased TC-NER capacity was associated with an increase in the sensitivity of tumour cells to cisplatin-induced apoptosis, even in p53 null and DNA mismatch repair-deficient cell lines.

Conclusion: The present work indicates that CSB and TC-NER play a prominent role in determining the sensitivity of tumour cells to cisplatin even in the absence of p53 and DNA mismatch repair. These results further suggest that CSB represents a potential target for cancer therapy that may be important to overcome resistance to cisplatin in the clinic.

Background

Cisplatin [cis-diammine-dichloroplatinum (II)] has been used in the treatment of neoplastic diseases for over 30 years [1]. The effectiveness of cisplatin is dependent on its interaction with DNA. This drug forms a variety of DNA adducts but more than 99% of these are intrastrand DNA adducts, most often between adjacent purines, with only a very small number of interstrand-crosslinks and monoadducts [2]. These intrastrand lesions are repaired by the nucleotide excision repair (NER) pathway so the response of tumours to cisplatin and other platinum-based drugs may be affected by nucleotide excision repair capacity of the tumour cells [1].

The vast majority of what is known about NER stems from studies using the model DNA damaging agent UV light but NER of cisplatin-induced DNA adducts is thought to occur through an identical mechanism [3-8]. The rate-limiting step in NER is lesion recognition and this occurs through two distinct mechanisms yielding two interrelated yet genetically separable subpathways of NER [9]. Global-genomic nucleotide excision repair (GG-NER) is responsible for the removal of the vast majority of UV and cisplatin-lesions throughout the genome whereas transcription-coupled nucleotide excision repair (TC-NER) is responsible for the selective removal of only those lesions that are present in the template strand of expressed genes [3,5,10-12].

Cockayne syndrome (CS) and xeroderma pigmentosum (XP) are heterogeneous disorders characterized by clinical photosensitivity [13]. Based on cell fusion and com-
plmentation studies, patients with CS were classified into two groups (CS groups A and B) whereas XP patients were grouped into 8 groups (XP groups A through G and V). CS and XP cells (with the exception of the variant form, XP-V) have defects in NER. These defects can be specific to TC-NER, GG-NER or both sub-pathways of NER [14,15]. Therefore, fibroblasts derived from patients with these UV sensitive syndromes have been instrumental in identifying proteins involved specifically in TC-NER and GG-NER and provided a model system to study the relative contribution of GG-NER and TC-NER to cisplatin response [6,16-18].

All TC-NER-deficient (CS-B for example) and completely NER-deficient (XP-A for example) fibroblasts were found to be exquisitely sensitive to apoptosis induced by UV light and cisplatin [6,16-18]. Many genetic alterations in cancer affect DNA damage responses. Notably, loss of the p53 tumour suppressor protein and DNA mismatch repair (MMR) proteins are among the most common genetic alterations in cancer and these alterations have been associated with resistance to cisplatin treatment [19-27]. Therefore, the effect of targeting TC-NER on the acute response of tumour cells to cisplatin could not be accurately predicted.

Here we report that silencing CSB by RNA interference (RNAi) reduced the TC-NER capacity of several prostate and colon cancer cell lines. This repair defect was associated with increased sensitivity of CSB-targeted cells to cisplatin-induced apoptosis. Importantly, the sensitivity of p53- and/or MMR-deficient tumour cells to cisplatin-induced apoptosis could be significantly increased by silencing CSB. These results suggest that TC-NER plays a major role in determining the sensitivity of these tumour cells to cisplatin and further suggests that CSB represents a potential therapeutic target for cancer therapy.

Methods

Cell Culture and UV-irradiation

HCT116, DU145 and PC-3 cells were obtained from the American Tissue Type Collection (Camden, NJ). The MLH1-corrected (HCT116 + chr3) and p53 nullizygous (HCT116p53-/-) cell lines were described previously [28,29]. HCT116 derived cells were cultured in McCoy's and DMEM were supplemented with 10% fetal bovine serum (Wisent, St. Bruno, QC). Where indicated, media (Wisent, St. Bruno, QC) while DU145 and PC-3 cells were grown in DMEM (Hyclone, Logan, UT).

McCoY's and DMEM were supplemented with 10% fetal bovine serum (Wisent, St. Bruno, QC). Where indicated, cisplatin (Mayne Pharma Canada Inc., Montreal, QC) was added to fresh, pre-warmed media at the indicated final concentration.

To UV-irradiate cells, medium was removed and cells were irradiated with the indicated dose using a germicidal bulb emitting predominantly at 254 nm at 1 J/m²/s as measured with a hand-held UV dosimeter (UVX Radiometer, UVP Inc., Uplands, CA). Fresh, pre-warmed media was replaced and dishes were returned to an incubator for the indicated period of time.

RNA interference

Sub-confluent cells were transfected with the indicated siRNA (Dharmacon, Lafayette, CO) using OptiMEM II and Oligofectamine (Invitrogen, Burlington, ON). The target sequences for CSB and XPA were GTGTGCAATTGCTTTACGA and AGAATTGCGGCAAGCAGTA, respectively. These RNA duplexes were used at a final concentration of 50 nM. A non-targeting control siRNA (TAGCGACTAAAACACATCAA) was used as a negative control.

Preparation of nuclear lysates

Cells were rinsed with phosphate buffered saline (PBS) then trypsinized and collected by centrifugation. Cell pellets were resuspended in nuclear extraction buffer (320 mM sucrose, 10 mM HEPES, 5 mM MgCl₂, 1% triton-X-100, pH 7.4), incubated on ice and then collected by centrifugation at 2500 × g. The resulting pellets were rinsed twice with nuclear wash buffer (320 mM sucrose, 10 mM HEPES, 5 mM MgCl₂, pH 7.4) and collected by centrifugation at 2500 × g then resuspended in RIPA buffer (50 mM Tris-HCl pH 6.8, 150 mM NaCl, 1 mM EDTA, 1% Triton-X-100, 1% sodium deoxycholate, 0.1% SDS). Pellets were disrupted using a sonicator equipped with a chilled microtip (Thermo Fisher Scientific, Ottawa, ON) and protein quantified using the Bradford assay (Bio-Rad, Mississauga, ON).

Immunoblotting

Two hundred micrograms of nuclear protein per well was subjected to gel electrophoresis using NuPAGE 3-8% gradient polyacrylamide gels (Invitrogen), to visualize CSB, whereas MLH1 and Ku86 were resolved using NuPAGE 4-12% gradient polyacrylamide gels (Invitrogen). Proteins were transferred to Hybond-C nitrocellulose (GE Healthcare, Baie d’Urfé, QC) and blots were stained with Ponceau S Red (5 mg/ml Ponceau S Red, 2% glacial acetic acid) to visualize total transferred proteins. Blots were then blocked in PBSMT-A (PBS, 5% nonfat milk powder, 0.05% Tween 20) and blotted with the indicated antibodies against XPA (FL-273), CSB (E-18) and Ku86 (M-20) (Santa Cruz Biotech, Santa Cruz, CA) and against MLH-1 (clone G168-15, BD Biosciences, Mississauga, ON) diluted in PBSMT-B (PBS, 0.5% nonfat milk powder) and were visualized using SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) in combination with X-ray film (Kodak, Rochester, NY). Multiple proteins were detected using the same blots using Restore Western Blot Stripping Buffer (Thermo Fisher Scientific).
The recovery of RNA synthesis
Sub-confluent cells were transfected with siRNA and subsequently grown in media supplemented with 5 μCi/ml of [14C] thymidine (GE Healthcare) to uniformly label DNA. Seventy-two hours later, cells were treated with 10 J/m² UV. One hour before indicated collection time, the media was replaced with fresh media containing 50 μCi/ml [3H] uridine (GE Healthcare) to label nascent RNA. Samples were rinsed in PBS containing 0.2% sodium azide (PBS-Z), collected by trypsin in PBS-Z, rinsed with PBS-Z and cell pellets were stored at -80°C. Samples were lysed in 1% SDS and nucleic acids were precipitated in 10% trichloroacetic acid (TCA)/0.1 M sodium pyrophosphate (NaPPi) and precipitated nucleic acids were collected on glass fiber filters (Thermo Fisher Scientific). Incorporation of [3H] and [14C] was determined using a scintillation counter and [3H] counts were normalized to [14C] counts to control for cell number. RNA synthesis is expressed as the proportion of [3H] uridine incorporated in UV-treated samples compared to unirradiated controls.

Host cell reactivation
Recombinant adenovirus expressing the lacZ gene under control of the murine cytomegalovirus promoter [30], was suspended in a minimal volume of PBS and was subsequently irradiated with the indicated dose of UV light on ice, as previously described [31]. Cells were infected with UV- or mock-treated AdlacZ at a multiplicity of infection of 5 plaque forming units per cell. Forty-eight hours following infection, media was removed and monolayers were incubated with 1 mM chloroformolred-β-D-galactopyranoside (Fluka Biochemika, Buchs, Switzerland) in 0.01% Triton X-100, 1 mM MgCl₂, and 100 β-D-galactosidase activity from the indicated dose is expressed as the proportion of cells with subdiploid DNA content.

Caspase activity assays
Cells were transfected with the indicated siRNA and treated with either UV light or cisplatin. Twenty four hours following treatment, cells were collected with trypsin, rinsed thoroughly with PBS and cell number was determined using an automated cell counter (Vi-Cell XR, Beckman Coulter). Caspase 3, 8 and 9 activities were determined from 1 × 10⁶ cells using ApoAlert caspase-3, caspase-8 or caspase-9/6 Fluorescent Assay Kits as specified by the manufacturer (Clontech, Mountain View, CA). Fluorescence was measured using a Thermo Fluoroskan Ascent microplate fluorometer (Thermo Fisher Scientific).

Results
RNA interference against CSB increased the sensitivity of prostate cancer cells to cisplatin-induced apoptosis
Prostate cancer cells (DU145 and PC-3 cells) were transfected with control or anti-CSB siRNAs and CSB protein levels were assessed by immunoblot analysis (Figure 1A). A single UV-induced dimer in the template strand of an active gene is sufficient to block its expression [34-36]. This principal forms the fundamental basis of host cell reactivation (HCR) assay that is commonly used to measure the repair of transcription-blocking DNA lesions [31,36-38]. The DU145 and PC-3 cells exhibited a similar dose-dependent decrease in β-galactosidase activity, suggesting that these cell lines have a similar capacity to repair transcription-blocking UV lesions (Figure 1B). Transfection of siRNAs directed against CSB led to a significant decrease in HCR of the UV-damaged reporter gene in both prostate cancer cell lines (Figure 1B). The dose of UV light required to reduce β-galactosidase activity to 50% (D50) was significantly lower in CSB targeted cells compared to control siRNA transfected cells (Figure 1C). Therefore, silencing CSB by RNAi resulted in impaired TC-NER, allowing us to assess the contribution of TC-NER to cisplatin response in these tumour cells.

The expression of CSB was similarly inhibited by RNAi and the sensitivity of PC-3 and DU145 cells to cisplatin-induced apoptosis was assessed. Silencing CSB led to a large increase in the sensitivity of DU145 cells to cisplatin-induced apoptosis (Figure 1D). The increased sensitivity of PC-3 cells was evident albeit less pronounced (Figure 1D). These results indicate that the ability of these prostate cancer cell lines to repair transcription-blocking DNA lesions by TC-NER was significantly reduced when CSB levels were decreased by RNAi. Importantly, these results suggest that disruption of CSB may be beneficial in combination with platinum-based drugs in the management of prostate cancer.
Role of p53 and MLH1 in determining cisplatin response of CSB-targeted colon cancer cells

Tumour cells frequently express mutant forms of DNA damage response proteins that may influence their sensitivity to therapeutic agents like cisplatin. For example, loss of p53 and MMR have been associated with resistance to cisplatin [19-23,25]. Notably, DU145 cells carry point mutations in both alleles of p53 and do not express MLH1 so they are MMR- and p53-deficient [39,40]. Similarly, PC-3 cells do not express detectable p53 and they exhibit microsatellite instability indicative of a defect in MMR [39,40]. Given the effect of targeting CSB in these p53 and MMR-deficient prostate cancer cell lines, an isogenic series of cell lines derived from HCT116 colorectal cancer cells were used to better assess the impact of p53- and MMR-deficiency under conditions in which CSB is silenced by RNAi.

HCT116 cells express wildtype p53 but do not express MLH1 and are considered MMR-defective [28]. The anti-CSB siRNA reduced CSB protein levels by more than 90% in these cells (Figure 2A) and this led to a decrease in their ability to repair an UV-damaged reporter gene (Figure 2B). Specifically, the dose of UV light required to reduce β-galactosidase activity to 50% (D50) was significantly lower in CSB-targeted HCT116 cells compared to control siRNA transfected cells. As a second measure of TC-NER, we assessed the ability of cells to recover nascent RNA synthesis following UV exposure. Whereas mock and control siRNA transfected cells recovered nascent RNA synthesis within 8 hours following exposure to 10 J/m² of UV light, the incorporation of [3H] uridine was still significantly inhibited 24 hours following UV exposure of CSB siRNA transfected HCT116 cells (Figure 2C). Taken together, silencing CSB led to a reduction in the capacity of HCT116 cells to perform TC-NER.

HCT116 were transfected with control and anti-CSB siRNAs and their sensitivity to cisplatin-induced apoptosis was assessed. Consistent with the results in prostate cancer cell lines, targeting CSB in HCT116 cells increased their sensitivity to cisplatin-induced apoptosis (Figure 2D) and this was associated with increased caspase activity (Figures 2E-G). Taken together, silencing CSB by RNAi reduced the capacity of these MMR-deficient cells to repair transcription-blocking DNA lesions and greatly increased their sensitivity to cisplatin-induced apoptosis.

Similar experiments were performed in an MLH1-corrected MMR-proficient subline of HCT116 cells (HCT116 + chr3) (Figure 3A and 3B) [28]. Again, targeting CSB by RNAi in these cells inhibited HCR of the UV-damaged reporter gene and prevented the efficient recovery of nascent RNA synthesis (Figures 3C and 3D). Furthermore, RNAi against CSB increased the sensitivity of CSB-targeted cells to cisplatin-induced apoptosis and this was associated with significant increases in the activity of caspases 3, 8 and 9 (Figures 3E-H). Taken together, MLH1 had no apparent effect on TC-NER of UV-induced DNA lesions or the sensitivity of these cells to cisplatin-induced apoptosis. Targeting CSB by RNAi was equally effective at increasing the sensitivity of these tumour cells to cisplatin-induced apoptosis, regardless of MLH1 expression.

CSB was also silenced by RNAi in p53 nullizygous derivatives of HCT116 cells (HCT116p53-/cells) (Figure 4A). These p53 null cells appeared to be reduced in their capacity to repair the UV damaged reporter gene com-
pared to parental cells already and HCR of the UV-damaged reporter gene was not further reduced by siRNA against CSB (Figure 4B). Subtle defects in TC-NER have been reported using similar HCR assays in other p53-deficient cells [41]. Nonetheless, these cells had almost fully recovered nascent RNA synthesis within 8 hours following UV exposure and this was again delayed in CSB siRNA-transfected HCT116p53-/- cells (Figure 4C). Despite the apparent repair defect detected in the HCR experiments, the present results indicate that HCT116p53-/- cells are not fully TC-NER deficient because RNAi against CSB again abrogated the recovery of nascent RNA synthesis in these cells.

There was no significant increase in the proportion of control siRNA transfected HCT116p53-/- cells undergoing apoptosis following exposure to up to 15 μM of cisplatin indicating that these cells were relatively resistant to cisplatin-induced apoptosis compared to isogenic controls (Figure 4D). This is likely due to the disruption of the well-described pro-apoptotic activity of p53 in these nullizygous cells [42]. However, decreased expression of CSB was again associated with a significant increase in the sensitivity of tumour cells to cisplatin-induced apoptosis (Figure 4D). Apoptosis was associated with a significant increase in the activity of caspases 3, 8 and 9 (Figure 4E-G). So, while p53 nullizygous cells were less sensitive to cisplatin-induced apoptosis, targeting TC-NER was similarly effective at sensitizing HCT116p53-/- cells to cisplatin-induced cell death. Clearly, p53 was not absolutely required to sensitize tumour cells to cisplatin when CSB expression was decreased by RNAi.

**RNA interference against XPA sensitizes cancer cells to cisplatin**

The CS proteins have been known to participate in TC-NER for many years [14], however, the CS proteins may play an additional role in regulating transcription [43-45]. Therefore, the expression of another protein required for TC-NER was silenced by RNAi. XPA is a DNA damage binding protein that is required for both TC-NER and GG-NER to which no additional functions have been ascribed [46]. XPA protein levels were reduced by RNAi in HCT116, HCT116 + chr3 and HCT115p53-/- cells and the sensitivity of the targeted cells to cisplatin-induced apoptosis was assessed. Decreased expression of XPA was associated with a statistically significant increase in the sensitivity of all 3 cell lines to cisplatin-induced apoptosis (Figure 5). Taken together, decreased expression of CSB or XPA was associated with increased sensitivity of
tumour cells to cisplatin-induced apoptosis and this was largely independent of MMR and p53.

**Discussion**

**Link between nucleotide excision repair and sensitivity to cisplatin**

The contribution of TC-NER to cell survival following UV-irradiation or cisplatin treatment is thought to be cell type specific. For example, CS-B fibroblasts have a specific defect in TC-NER and are more sensitive to UV- and cisplatin-induced apoptosis than GG-NER deficient XP-C fibroblasts [6,16-18]. A similar relationship was reported in CSB nullizygous mouse embryonic fibroblasts and murine keratinocytes exposed to UV light [7,16,17,47-53]. By contrast, CSB null murine embryonic stem cells were not hypersensitive to this DNA damaging agent [52].

The CSB protein is required for a rate limiting step of TC-NER [56-58]. Here we show that a series of prostate and colon cancer cell lines retained the ability to repair transcription-blocking DNA lesions and that silencing CSB functionally impaired this repair process. Therefore, we were able to test the role of TC-NER in cisplatin response using this *in vitro* system. Decreased expression of CSB was associated with increased sensitivity of cells to cisplatin-induced apoptosis. Similarly, silencing CSB led to increased apoptosis following exposure to UV light (data not shown), consistent with a role for CSB in determining the sensitivity of cells to apoptosis induced by UV light and cisplatin.
both of these agents [6,16-18,50,59,60]. Lu and coworkers reported that antisense oligonucleotides designed to inhibit the expression of CSB increased the responsiveness of wildtype p53 and DNA mismatch repair proficient ovarian tumour xenografts to cisplatin [61]. Targeting TC-NER may represent a means of increasing the responsiveness of a variety of tumours to cisplatin.

**MMR proteins and p53 in cisplatin resistance**

Cisplatin is among the most widely used anti-neoplastic agents. Although tumours often respond favorably to cisplatin treatment, there is eventual disease progression in many cases. This recurrent disease can be refractory to subsequent treatment with platinum-based drugs [1,62-69]. Drug resistance can in some cases be attributed to increased DNA repair response but may also result from a variety of other alterations including decreased apoptotic signaling in response to this form of DNA damage [64,67,69-74]. Two key genetic changes that have been associated with resistance to cisplatin are p53- and MMR-deficiency [19,21-23,25,64,75-77]. Despite the association of p53 and MMR defects with cisplatin resistance, RNAi against CSB and XPA in this panel of tumour cell lines deficient in p53 (PC-3, DU145 and HCT116p53-/-) and MMR (PC-3, DU145, HCT116 and HCT116p53-/-) resulted in a significant increase in the sensitivity of cells to cisplatin-induced cell death. The present results indicate that targeting TC-NER sensitizes tumour cells to cisplatin-induced apoptosis and that this was largely independent of p53 and MMR. This makes TC-NER an attractive target for combined cancer therapy.

**Conclusion**

We found that both p53 and MMR-deficient colorectal and prostate cancer cells retain the ability to perform TC-
NER and targeting TC-NER in these cells increased their sensitivity to UV light and cisplatin. CSB and XPA may represent rational targets to augment cisplatin responsiveness of tumours, independent of MMR capacity and p53. This work further suggests that targeting other proteins involved in TC-NER may similarly represent a promising approach for cancer therapy. Notably, recent clinical evidence suggests that ERCC1 levels predict response to platinum-based therapies in non-small cells lung cancer [1,78-80], small cell lung cancer [81], esophageal cancer [82], head and neck cancer [83], bladder cancer [84] and testicular cancer [85]. ERCC1, like XPA, is required for both TC-NER and GG-NER. It is possible that the predictive value of ERCC1 is related to its role in TC-NER and that the expression of other proteins involved in TC-NER, like CSB, may also be predictors of therapeutic response in diverse tumours.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
LJS and BCM conceived of the study. LJS and JMS collected the data. LJS and BCM contributed to data analysis and wrote the manuscript with input from JMS. All authors read and approved the manuscript.

Acknowledgements
This work was supported by the Prostate Cancer Research Initiative, the National Canadian Institute of Cancer with funds from the Terry Fox Run and the Ottawa Regional Cancer Foundation with funds from the Motorcycle Ride for Dad. L.J.S. was supported by an Ontario Premier’s Research Excellence Award to B.C.M. and an Ontario Graduate Scholarship in Science and Technology. J.M.S. was supported with an Ontario Graduate Scholarship in Science and Technology. B.C.M. was supported with a Research Scientist of the National Cancer Institute of Canada supported with funds provided by the Canadian Cancer Society.

Figure 5 RNAi against XPA sensitizes colon cancer cells to cisplatin. HCT116, HCT116 + chr3 and HCT116p53/- cells were transfected with non-targeting control (NT) or XPA siRNA. These transfected cells were exposed to the indicated concentration of cisplatin and apoptosis was assessed 48 hours later by the proportion of cells with subdiploid DNA content. Each value represents the mean (± SEM) determined from a minimum of 3 independent experiments. An * indicates that the value is significantly different its respective NT control (P ≤ 0.05, t-test). Similar results were obtained following exposure to UV light (data not shown).

References
1. Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with plating agents. Cancer Treat Rev 2007, 33(1):9-23.
2. Kartalou M, Essigmann JM: Recognition of cisplatin adducts by cellular proteins. Mutat Res 2001, 478(1-2):1-21.
3. May A, Nairn RS, Okumoto DS, Wassermann K, Stevnsner T, Jones JC, Bohr VA: Repair of individual DNA strands in the hamster dihydrofolate reductase gene after treatment with ultraviolet light, alkylating agents, and cisplatin. J Biol Chem 1993, 268(3):1650-1657.
4. Zhen W, Link CJ Jr, O’Connor PA, Reed E, Parker R, Howell SB, Bohr VA: Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 1992, 12(9):3689-3698.
5. Jones JC, Zhen WP, Reed E, Parker RJ, Sancar A, Bohr VA: Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J Biol Chem 1991, 266(11):7101-7107.
6. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y: Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002, 62(17):4899-4902.
7. McKay BC, Chen F, Clarke ST, Wiggin HE, Harley LM, Ljungman M: UV light-induced degradation of RNA polymerase II is dependent on the Cockayne’s syndrome A and B proteins but not p53 or MLH1. Mutat Res 2001, 485(2):93-105.
8. Sancar A: DNA excision repair. Annu Rev Biochem 1996, 65:43-81.
9. Balaje AS, Bohr VA: Genomic heterogeneity of nucleotide excision repair. Gene 2000, 250(1-2):15-30.
10. Mellon I, Spivak G, Hanawalt PC: Selective removal of transcription-blocking DNA damage from the transcribed strand of the mammalian DHFR gene. Cell 1987, 51(2):241-249.
11. Tu Y, Bates S, Pfeifer GP: The transcription-repair coupling factor CSA is required for efficient repair only during the elongation stages of RNA polymerase II transcription. Mutat Res 1998, 400(1-2):143-151.
12. Tu Y, Bates S, Pfeifer GP: Sequence-specific and domain-specific DNA repair in xeroderma pigmentosum and Cockayne syndrome cells. J Biol Chem 1997, 272(33):20747-20755.
13. Cleaver JE: Ultraviolet photobiology: its early roots and insights into DNA repair. DNA Repair (Amst) 2002, 1(11):977-979.
14. van Hoffen A, Natarajan AT, Mayne LV, van Zeeland AA, Mullenders LH, Venema J: Deficient repair of the transcribed strand of active genes in Cockayne’s syndrome cells. Nucleic Acids Res 1993, 21(25):5890-5895.
15. Venema J, van Hoffen A, Karagiuc V, Natarajan AT, van Zeeland AA, Mullenders LH: Xeroderma pigmentosum complementation group C cells remove pyrimidine dimers selectively from the transcribed strand of active genes. Mol Cell Biol 1991, 11(8):4128-4134.
16. Andera L, Wasylyk B: Transcription abnormalities potentiate apoptosis of normal human fibroblasts. Mol Med 1997, 3(12):852-863.
17. McKay BC, Becerill C, Ljungman M: P53 plays a protective role against UV- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts. Oncogene 2001, 20(46):6805-6808.
18. Ljungman M, Zhang F, Chen F, Rainbow AJ, McKay BC: Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 1999, 18(5):583-592.
19. Fajas A, Da Silva J, Ahomadegbe JC, Rateau JG, Bernaudin JF, Riou G, Benard J: Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 1996, 68(1):67-74.
20. Righetti SC, Perego P, Corna E, Pierotti MA, Zunino F: Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneous mutant selection. Cell Growth Differ 1999, 10(7):473-478.
is not due to defective transcription-coupled repair of active genes. 

43. Proietti-De-Santis L, Drake P, Ely JM. Cockayne syndrome B protein regulates the transcriptional program after UV irradiation. Embo J 2006, 25(9):1915-1923.

44. Dianov GL, Houle JF, Iyer N, Rohr VA, Friedberg EC. Reduced RNA polymerase II transcription in extracts of cockayne syndrome and xeroderma pigmentosum/Cockayne syndrome cells. Nucleic Acids Res 1997, 25(18):3636-3645.

45. Friedberg EC, Aguilera A, Gellert M, Hanawalt PC, Hays JB, Lehmann AR. Logothetis I, Lowndes N, Sarasin A, Wood RD. DNA repair: from molecular mechanism to human disease. DNA Repair (Amst) 2006, 5(8):986-996.

46. McKay BC, Ljungman M. Role for p53 in the recovery of transcription and protection against apoptosis induced by ultraviolet light. Neoplasia 1999, 1(3):276-284.

47. McKay BC, Ljungman M, Rainbow AJ. Persistent DNA damage induced by ultraviolet light inhibits p21waf1 and bax expression: implications for DNA repair, UV sensitivity and the induction of apoptosis. Oncogene 1998, 17(5):545-555.

48. Quelle S, Drougard C, Sarasin A, Daya-Grosjean L. Effects of XP D mutations on ultraviolet-induced apoptosis in relation to skin cancer-promotion in repair-deficient strains. J Invest Dermatol 2001, 117(5):1162-1170.

49. Ljungman M, Zhang F. Blockage of RNA polymerase as a possible trigger for u.v. light-induced apoptosis. Oncogene 1996, 13(4):823-831.

50. Shain DE, Winkonikal NW, Remenyik E, Horst GT van der, Friedberg EC, Cheo DL, van Steeg H, Westerman A, van Kranen Lu Y, Mani S, Kandimalla ER, Yu D, Agrawal S, States JC, Bregman DB. Wildtype p53 is required for heat shock and ultraviolet light enhanced repair of a UV-damaged reporter. DNA Repair (Amst) 2001, 1(12):23-43.

51. Clement V, Dunand-Sastier I, Clarkson SG. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homzygous hMLH1 mutation. Cancer Res 1994, 54(16):4308-4312.

52. Buzy P, Dutraux A, Lengauer C, Walchli. Zhu S, Brown JP, Sedov JIM, Kondor KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282(5393):1497-1501.

53. Addison CL, Hitt M, Kuninken D, Graham FL. Comparison of the human versus murine cytochrome b5m4m immediately early gene promoters for transgene expression by adenovectoral vectors. J Virol 1997, 71(7):653-661.

54. Proietti-De-Santis L, Drane P, Egly JM. Cockayne syndrome B protein as an anti-cancer trigger for u.v. light-induced apoptosis. Cancer Res 2006, 66(11):556-562.

55. Proietti-De-Santis L, Drake P, Ely JM. Cockayne syndrome B protein regulates the transcriptional program after UV irradiation. Embo J 2006, 25(9):1915-1923.

56. Dianov GL, Houle JF, Iyer N, Rohr VA, Friedberg EC. Reduced RNA polymerase II transcription in extracts of cockayne syndrome and xeroderma pigmentosum/Cockayne syndrome cells. Nucleic Acids Res 1997, 25(18):3636-3645.

57. Friedberg EC, Aguilera A, Gellert M, Hanawalt PC, Hays JB, Lehmann AR. Logothetis I, Lowndes N, Sarasin A, Wood RD. DNA repair: from molecular mechanism to human disease. DNA Repair (Amst) 2006, 5(8):986-996.

58. McKay BC, Ljungman M. Role for p53 in the recovery of transcription and protection against apoptosis induced by ultraviolet light. Neoplasia 1999, 1(3):276-284.

59. McKay BC, Ljungman M, Rainbow AJ. Persistent DNA damage induced by ultraviolet light inhibits p21waf1 and bax expression: implications for DNA repair, UV sensitivity and the induction of apoptosis. Oncogene 1998, 17(5):545-555.

60. Quelle S, Drougard C, Sarasin A, Daya-Grosjean L. Effects of XP D mutations on ultraviolet-induced apoptosis in relation to skin cancer-promotion in repair-deficient strains. J Invest Dermatol 2001, 117(5):1162-1170.

61. Ljungman M, Zhang F. Blockage of RNA polymerase as a possible trigger for u.v. light-induced apoptosis. Oncogene 1996, 13(4):823-831.

62. Shain DE, Winkonikal NW, Remenyik E, Horst GT van der, Friedberg EC, Cheo DL, van Steeg H, Westerman A, van Kranen Lu Y, Mani S, Kandimalla ER, Yu D, Agrawal S, States JC, Bregman DB. Wildtype p53 is required for heat shock and ultraviolet light enhanced repair of a UV-damaged reporter. DNA Repair (Amst) 2001, 1(12):23-43.
65. Gonzalez-Martin A. Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy. *Int J Gynecol Cancer* 2005, 15(Suppl 3):241-246.
66. Wang D. Lipari J. Cellular processing of platinum anticancer drugs. *Nat Rev Drug Discov* 2005, 4(4):307-320.
67. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. *Crit Rev Oncol Hematol* 2007, 63(1):12-31.
68. Tao X, Hu W, Ramirez PT, Kavanagh JJ. Chemotherapy for recurrent and metastatic cervical cancer. *Gynecol Oncol* 2008, 110(3 Suppl 2):657-71.
69. Muggia F. Platinum compounds: 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. *Gynecol Oncol* 2009, 112(1):275-281.
70. Chao CC. Enhanced excision repair of DNA damage due to cis-diaminedichloroplatinum(II) in resistant cervix carcinoma HeLa cells. *Eur J Pharmacol* 1994, 268(3):347-355.
71. Zamble DB, Lipari J. Cisplatin and DNA repair in cancer chemotherapy. *Trends Biochem Sci* 1995, 20(10):435-439.
72. Petersen LN, Maman N, Stenvsner T, Cheney SG, Bohr VA. Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity. *Carcinogenesis* 1996, 17(12):2597-2602.
73. Damia G, Guidi G, D'Incalci M. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. *Eur J Cancer* 1998, 34(11):1783-1788.
74. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. *Biochem Pharmacol* 2000, 60(9):1305-1313.
75. Lupi M, Matera G, Natoli C, Colombo V, Libenzio P. The contribution of p53 in the dynamics of cell cycle response to DNA damage interpreted by a mathematical model. *Cell Cycle* 2007, 6(8):943-950.
76. Bhana S, Lloyd DR. The role of p53 in DNA damage-mediated cytotoxicity overrides its ability to regulate nucleotide excision repair in human fibroblasts. *Mutagenesis* 2008, 23(1):43-50.
77. Vazquez A, Bond EE, Levine AJ, Bond G. The genetics of the p53 pathway, apoptosis and cancer therapy. *Nat Rev Drug Discov* 2008, 7(12):979-987.
78. Simon GP, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. *Chest* 2005, 127(3):978-983.
79. Felipe E, Rosell R. Testing for excision repair cross-complementing 1 in patients with non-small cell lung cancer for chemotherapy response. *Expert Rev Mol Diagn* 2007, 7(3):261-268.
80. Olausen KA, Muntzgos M, Soria JC. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. *Curr Opin Pulm Med* 2007, 13(4):284-289.
81. Ceppi P, Longo M, Valiente M, Novello S, Cappa S, Bacillo E, Selvaggi G, Saviozzi S, Calogero R, Papotti M, et al. Excision repair cross complementing-1 and topoisomerase I alpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study. *J Thorac Oncol* 2008, 3(6):583-589.
82. Kim MK, Cho K, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, et al. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. *Clin Cancer Res* 2008, 14(13):4225-4231.
83. Handra-Luca A, Hernandez J, Mountzgos G, Taranchon E, Lacau-St-Guily J, Soria JC, Four R. Excision repair complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. *Clin Cancer Res* 2007, 13(13):3855-3859.
84. Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albli N, Gillem G, Gallardo E, Carles J, Mendez P, de la Cruz JJ, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. *Ann Oncol* 2007, 18(3):522-528.
85. Welch C, Day R, McMurk C, Masters JR, Wood RD, Koberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. *Int J Cancer* 2004, 110(3):352-361.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/207/prepub